R. Scott Greer's most recent trade in Nektar Therapeutics was a trade of 8,000 Stock Option done . Disclosure was reported to the exchange on Sept. 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nektar Therapeutics | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2025 | 8,000 | 8,000 | - | - | Stock Option | |
| Nektar Therapeutics | R. Scott Greer | Director | 31 Dec 2024 | 120,000 | 120,000 | - | - | Stock Option | ||
| Nektar Therapeutics | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 20,400 | 20,400 | - | - | Stock Option | |
| Nektar Therapeutics | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 10,200 | 303,574 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 12,500 | 0 | - | - | Stock Option | |
| Nektar Therapeutics | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.80 per share. | 09 Nov 2021 | 12,500 | 293,374 (0%) | 0% | 12.8 | 160,000 | Common Stock |
| Nektar Therapeutics | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 20,400 | 20,400 | - | - | Stock Option | |
| Nektar Therapeutics | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 10,200 | 280,874 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.70 per share. | 31 Aug 2021 | 45,000 | 270,674 (0%) | 0% | 12.7 | 571,500 | Common Stock |
| Nektar Therapeutics | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2021 | 45,000 | 0 | - | - | Stock Option | |
| Inogen Inc | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 2,754 | 30,775 (0%) | 0% | 0 | Common Stock | |
| Inogen Inc | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2021 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Inogen Inc | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.19 per share. | 03 Feb 2021 | 10,000 | 28,021 (0%) | 0% | 44.2 | 441,900 | Common Stock |
| Inogen Inc | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2021 | 6,666 | 0 | - | - | Stock Option (right to buy) | |
| Inogen Inc | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.66 per share. | 03 Feb 2021 | 6,666 | 14,687 (0%) | 0% | 46.7 | 311,036 | Common Stock |
| Inogen Inc | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2021 | 3,334 | 0 | - | - | Stock Option (right to buy) | |
| Inogen Inc | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.21 per share. | 03 Feb 2021 | 3,334 | 18,021 (0%) | 0% | 43.2 | 144,062 | Common Stock |